258 related articles for article (PubMed ID: 28157583)
1. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
4. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
6. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
9. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer.
Botteri E; Sandri MT; Bagnardi V; Munzone E; Zorzino L; Rotmensz N; Casadio C; Cassatella MC; Esposito A; Curigliano G; Salvatici M; Verri E; Adamoli L; Goldhirsch A; Nolè F
Breast Cancer Res Treat; 2010 Jul; 122(1):211-7. PubMed ID: 19967556
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS
Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939
[TBL] [Abstract][Full Text] [Related]
11. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
12. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
15. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
16. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.
Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC
Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515
[TBL] [Abstract][Full Text] [Related]
17. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer.
Liu MC; Shields PG; Warren RD; Cohen P; Wilkinson M; Ottaviano YL; Rao SB; Eng-Wong J; Seillier-Moiseiwitsch F; Noone AM; Isaacs C
J Clin Oncol; 2009 Nov; 27(31):5153-9. PubMed ID: 19752342
[TBL] [Abstract][Full Text] [Related]
19. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
